Healthcare -
Biotechnology - NASDAQ - US
$ 3.6
2.86 %
$ 308 M
Market Cap
-0.94
P/E
1. INTRINSIC VALUE
Balance Sheet
Amylyx Pharmaceuticals, Inc.
| Current Assets | 465 M |
| Cash & Short-Term Investments | 371 M |
| Receivables | 40 M |
| Other Current Assets | 53.3 M |
| Non-Current Assets | 52.8 M |
| Long-Term Investments | 0 |
| PP&E | 6.41 M |
| Other Non-Current Assets | 46.4 M |
| Current Liabilities | 82 M |
| Accounts Payable | 22.1 M |
| Short-Term Debt | 2.26 M |
| Other Current Liabilities | 57.7 M |
| Non-Current Liabilities | 1.98 M |
| Long-Term Debt | 1.98 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Amylyx Pharmaceuticals, Inc.
| Revenue | 381 M |
| Cost Of Revenue | 25.4 M |
| Gross Profit | 355 M |
| Operating Expenses | 317 M |
| Operating Income | 38.8 M |
| Other Expenses | -10.5 M |
| Net Income | 49.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Amylyx Pharmaceuticals, Inc.
| Net Income | 49.3 M |
| Depreciation & Amortization | 1.09 M |
| Capital Expenditures | -1.24 M |
| Stock-Based Compensation | 37.2 M |
| Change in Working Capital | -65.7 M |
| Others | -91.5 M |
| Free Cash Flow | 10.7 M |
Wall Street Analysts Price Targets
Amylyx Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for AMLX of $5.88 , with forecasts ranging from
a
low of
$3 to a high of $11 .
AMLX Lowest Price Target
Wall Street Target
3 USD
-16.67%
AMLX Average Price Target
Wall Street Target
5.88 USD
63.19%
AMLX Highest Price Target
Wall Street Target
11 USD
205.56%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.42 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Amylyx Pharmaceuticals, Inc.
Sold
0-3 MONTHS
30 K USD 1
3-6 MONTHS
183 K USD 4
6-9 MONTHS
19.7 K USD 1
9-12 MONTHS
271 K USD 4
Bought
0 USD 0
0-3 MONTHS
428 K USD 3
3-6 MONTHS
9.44 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 month ago
Dec 02, 2024
|
Sell 30 K
USD
|
Bedrosian Camille L
Chief Medical Officer
|
- 5421
|
5.5354 USD |
|
3 months ago
Sep 30, 2024
|
Sell 59.4 K
USD
|
Klee Justin B.
Co-Chief Executive Officer
|
- 18589
|
3.197 USD |
|
3 months ago
Sep 30, 2024
|
Sell 59.4 K
USD
|
Cohen Joshua B
Co-Chief Executive Officer
|
- 18589
|
3.1962 USD |
|
3 months ago
Sep 30, 2024
|
Sell 36.6 K
USD
|
Bedrosian Camille L
Chief Medical Officer
|
- 11442
|
3.1952 USD |
|
3 months ago
Sep 30, 2024
|
Sell 27.8 K
USD
|
Mazzariello Gina
Chief Legal Officer
|
- 8709
|
3.1967 USD |
|
4 months ago
Sep 12, 2024
|
Bought
101 K USD
|
FRATES JAMES M
Chief Financial Officer
|
+ 40000
|
2.5342 USD |
|
4 months ago
Sep 05, 2024
|
Bought
107 K USD
|
Firestone Karen
Director
|
+ 50000
|
2.1318 USD |
|
4 months ago
Sep 03, 2024
|
Bought
220 K USD
|
MILNE GEORGE M JR
Director
|
+ 100000
|
2.198 USD |
|
8 months ago
May 15, 2024
|
Bought
4.25 K USD
|
Quimi Daphne
Director
|
+ 2250
|
1.8899 USD |
|
8 months ago
May 14, 2024
|
Bought
5.18 K USD
|
Quimi Daphne
Director
|
+ 2750
|
1.885 USD |
|
8 months ago
May 15, 2024
|
Sell 19.7 K
USD
|
Mazzariello Gina
Chief Legal Officer
|
- 10455
|
1.8799 USD |
|
10 months ago
Mar 05, 2024
|
Sell 77.4 K
USD
|
Cohen Joshua B
Co-Chief Executive Officer
|
- 4135
|
18.7279 USD |
|
10 months ago
Mar 05, 2024
|
Sell 77.4 K
USD
|
Klee Justin B.
Co-Chief Executive Officer
|
- 4135
|
18.7279 USD |
|
10 months ago
Mar 05, 2024
|
Sell 33.6 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 1792
|
18.7279 USD |
|
10 months ago
Mar 05, 2024
|
Sell 28.8 K
USD
|
Mazzariello Gina
Chief Legal Officer
|
- 1540
|
18.7279 USD |
|
10 months ago
Feb 23, 2024
|
Sell 53.2 K
USD
|
Mazzariello Gina
Chief Legal Officer
|
- 2838
|
18.7564 USD |
|
1 year ago
Jan 09, 2024
|
Sell 95.4 K
USD
|
Klee Justin B.
Co-Chief Executive Officer
|
- 5841
|
16.3281 USD |
|
1 year ago
Jan 09, 2024
|
Sell 44.3 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 2716
|
16.3281 USD |
|
1 year ago
Jan 09, 2024
|
Sell 95.4 K
USD
|
Cohen Joshua B
Co-Chief Executive Officer
|
- 5841
|
16.3281 USD |
|
1 year ago
Jan 09, 2024
|
Sell 45.9 K
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 2812
|
16.3281 USD |
|
1 year ago
Dec 15, 2023
|
Bought
59.9 K USD
|
Firestone Karen
Director
|
+ 4000
|
14.97 USD |
|
1 year ago
Aug 15, 2023
|
Sell 129 K
USD
|
Mazzariello Gina
Chief Legal Officer
|
- 6164
|
20.8771 USD |
|
1 year ago
May 16, 2023
|
Sell 862 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 32000
|
26.9266 USD |
|
1 year ago
May 16, 2023
|
Sell 13.8 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 500
|
27.6 USD |
|
1 year ago
May 15, 2023
|
Sell 347 K
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 11965
|
29.0312 USD |
|
1 year ago
Apr 17, 2023
|
Sell 1.5 M
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 49279
|
30.5335 USD |
|
1 year ago
Apr 17, 2023
|
Sell 9.28 K
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 300
|
30.94 USD |
|
1 year ago
Mar 29, 2023
|
Sell 885 K
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 29048
|
30.45 USD |
|
1 year ago
Mar 27, 2023
|
Sell 997 K
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 32964
|
30.25 USD |
|
1 year ago
Mar 27, 2023
|
Sell 862 K
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 28000
|
30.8 USD |
|
1 year ago
Mar 28, 2023
|
Sell 3.04 M
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 100000
|
30.37 USD |
|
1 year ago
Mar 16, 2023
|
Sell 981 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 30796
|
31.8593 USD |
|
1 year ago
Mar 16, 2023
|
Sell 55.3 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 1704
|
32.4649 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.66 M
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 52211
|
31.8485 USD |
|
1 year ago
Mar 16, 2023
|
Sell 78.4 K
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 2416
|
32.4331 USD |
|
1 year ago
Mar 21, 2023
|
Sell 1.1 M
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 34641
|
31.69 USD |
|
1 year ago
Mar 21, 2023
|
Sell 927 K
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 28807
|
32.17 USD |
|
1 year ago
Mar 16, 2023
|
Sell 3.07 M
USD
|
Klee Justin B.
Co-Chief Executive Officer
|
- 96555
|
31.8405 USD |
|
1 year ago
Mar 16, 2023
|
Sell 112 K
USD
|
Klee Justin B.
Co-Chief Executive Officer
|
- 3445
|
32.4751 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.05 M
USD
|
MILNE GEORGE M JR
Director
|
- 33084
|
31.8553 USD |
|
1 year ago
Mar 16, 2023
|
Sell 62.2 K
USD
|
MILNE GEORGE M JR
Director
|
- 1916
|
32.4487 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.66 M
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 52211
|
31.8485 USD |
|
1 year ago
Mar 16, 2023
|
Sell 78.4 K
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 2416
|
32.4331 USD |
|
1 year ago
Mar 16, 2023
|
Bought
32 K USD
|
Firestone Karen
Director
|
+ 1000
|
31.99 USD |
|
1 year ago
Mar 16, 2023
|
Sell 3.06 M
USD
|
Cohen Joshua B
Co-Chief Executive Officer
|
- 96076
|
31.8396 USD |
|
1 year ago
Mar 16, 2023
|
Sell 127 K
USD
|
Cohen Joshua B
Co-Chief Executive Officer
|
- 3924
|
32.4451 USD |
|
1 year ago
Mar 16, 2023
|
Sell 981 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 30796
|
31.8593 USD |
|
1 year ago
Mar 16, 2023
|
Sell 55.3 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 1704
|
32.4649 USD |
|
1 year ago
Mar 16, 2023
|
Sell 297 K
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 9122
|
32.55 USD |
|
1 year ago
Mar 14, 2023
|
Sell 2.44 M
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 70714
|
34.54 USD |
|
1 year ago
Mar 15, 2023
|
Sell 3.61 M
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 108934
|
33.12 USD |
|
1 year ago
Mar 15, 2023
|
Sell 1.38 M
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 41066
|
33.68 USD |
|
1 year ago
Mar 02, 2023
|
Sell 1.69 M
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 50000
|
33.75 USD |
|
1 year ago
Feb 24, 2023
|
Sell 124 K
USD
|
Mazzariello Gina
Chief Legal Officer
|
- 3586
|
34.4874 USD |
|
1 year ago
Feb 22, 2023
|
Sell 1.66 M
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 47888
|
34.7 USD |
|
1 year ago
Feb 22, 2023
|
Sell 74.6 K
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 2112
|
35.34 USD |
|
1 year ago
Feb 22, 2023
|
Sell 1.43 M
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 39916
|
35.91 USD |
|
1 year ago
Feb 22, 2023
|
Sell 366 K
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 10084
|
36.34 USD |
|
1 year ago
Feb 23, 2023
|
Sell 1.74 M
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 48889
|
35.55 USD |
|
1 year ago
Feb 23, 2023
|
Sell 40.3 K
USD
|
Morningside Venture Investments Ltd
10 percent owner
|
- 1111
|
36.24 USD |
|
2 years ago
Jan 06, 2023
|
Sell 50.7 K
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 1405
|
36.0789 USD |
|
2 years ago
Jan 06, 2023
|
Sell 23.1 K
USD
|
Yeramian Patrick D
Chief Medical Officer
|
- 629
|
36.7888 USD |
|
2 years ago
Jan 06, 2023
|
Sell 149 K
USD
|
Cohen Joshua B
Co-Chief Executive Officer
|
- 4122
|
36.0789 USD |
|
2 years ago
Jan 06, 2023
|
Sell 67.9 K
USD
|
Cohen Joshua B
Co-Chief Executive Officer
|
- 1846
|
36.7888 USD |
|
2 years ago
Jan 06, 2023
|
Sell 66.2 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 1836
|
36.0789 USD |
|
2 years ago
Jan 06, 2023
|
Sell 30.2 K
USD
|
FRATES JAMES M
Chief Financial Officer
|
- 822
|
36.7888 USD |
|
2 years ago
Jan 06, 2023
|
Sell 59.9 K
USD
|
Olinger Margaret
Chief Commercial Officer
|
- 1660
|
36.0789 USD |
|
2 years ago
Jan 06, 2023
|
Sell 27.3 K
USD
|
Olinger Margaret
Chief Commercial Officer
|
- 743
|
36.7888 USD |
|
2 years ago
Jan 06, 2023
|
Sell 149 K
USD
|
Klee Justin B.
Co-Chief Executive Officer
|
- 4122
|
36.0789 USD |
|
2 years ago
Jan 06, 2023
|
Sell 67.9 K
USD
|
Klee Justin B.
Co-Chief Executive Officer
|
- 1846
|
36.7888 USD |
|
2 years ago
Jul 06, 2022
|
Sell 358 K
USD
|
ALS Invest 1 B.V.
director:
|
- 18312
|
19.54 USD |
|
3 years ago
Jan 11, 2022
|
Bought
5 M USD
|
Morningside Venture Investments Ltd
10 percent owner
|
+ 263158
|
19 USD |
|
3 years ago
Jan 11, 2022
|
Bought
5 M USD
|
Morningside Venture Investments Ltd
10 percent owner
|
+ 263158
|
19 USD |
|
3 years ago
Jan 11, 2022
|
Bought
43.7 M USD
|
VIKING GLOBAL INVESTORS LP
|
+ 2300000
|
19 USD |
|
3 years ago
Jan 06, 2022
|
Bought
75 K USD
|
FONTEYNE PAUL R.
Director
|
+ 3947
|
19 USD |
|
3 years ago
Jan 06, 2022
|
Bought
125 K USD
|
Cheng Isaac
Director
|
+ 6578
|
19 USD |
|
3 years ago
Jan 06, 2022
|
Bought
500 K USD
|
MILNE GEORGE M JR
Director
|
+ 26315
|
19 USD |
|
3 years ago
Jan 06, 2022
|
Bought
130 K USD
|
Olinger Margaret
Chief Commercial Officer
|
+ 6842
|
19 USD |
7. News
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 1 week ago
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer.
businesswire.com
- 1 week ago
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 1 week ago
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 1 month ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
accesswire.com
- 1 month ago
8. Profile
Summary
Amylyx Pharmaceuticals, Inc. AMLX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 308 M
Dividend Yield
0.00%
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Contact
43 Thorndike Street, Cambridge, MA, 02141
https://amylyx.com
IPO
Date
Jan. 7, 2022
Employees
384
Officers
Ms. Gina M. Mazzariello J.D.
Chief Legal Officer & General Counsel
Ms. Lindsey Allen
Head of Investor Relations & Communications
Ms. Shauna Horvath
Head of Global Marketing
Mr. Joshua B. Cohen
Co-Founder, Co-Chief Executive Officer & Director
Mr. Justin B. Klee
Co-Founder, Co-Chief Executive Officer & Director
Mr. James M. Frates M.B.A.
Chief Financial Officer
Dr. Camille L. Bedrosian M.D.
Chief Medical Officer
Mr. Tom Holmes
Chief Technical Operations Officer
Ms. Linda A. Arsenault
Chief Human Resources Officer
Mr. Chris Aiello
Head of Canada & GM